CSL challenger Aegros to build Singapore plasma plant
Aegros has delayed a potential ASX float by another year as it completes a flurry of deals and investments to prove that it’s not just another ‘biotech gonna’.
Csl
Is this the wonder drug to send CSL shares back over $300?
The blockbuster new drug to cure haemophilia with one $3.5m shot has finally made its way to the first patient – boosting hopes for CSL’s $1bn franchise.
ASX rises 0.2pc; best win streak since April
Another of rate cuts in China lifts dollar. IAG closes at three-year high. Australia sees first post-GFC bond inversion. ANZ ups rate peak after hot jobs data. DGL tanks on update.
CSL shares dive on $370m foreign currency hit
Joy Linton, chief financial officer of the ASX-listed health titan, says it will be ‘some time’ before margins return to pre-pandemic levels.
ASX rises; FMG’s best day of 2023, CSL dives 7pc
Fortescue sees strongest gain this year. CSL hammered on foreign currency hit. Gas industry to increase supply. Citi warns on coal sector. Consumer confidence at three-year low.
ASX health small caps dishing out dividends
Small cap health stocks commonly don’t pay dividends. But these ASX players have been handing out – not burning through – cash.
If CSL is a bellwether – what is it telling us?
The only world-ranking ASX company that is not a bank or a miner has been drifting for months. Whether that’s good or bad, depends on what likely follows next.
Shot in the arm for CSL’s $800m flu vaccine factory
A new factory in Melbourne’s northern suburbs will form the centrepiece of CSL’s arsenal in fighting future pandemics.
Harsh reality check for green hydrogen fantasy
Nick Cater’s comparison of coal and wind turbines’ capacity to deliver a per megawatt of electricity, and the density that requires, is revealing.
Wave of sickness: CSL accelerates flu jab release
More than 8 million influenza vaccines have hit public and private providers as Australia’s biggest health company CSL predicts the worst season in a decade.
Reliable energy remains the key issue despite distractions
It defies belief that the NSW government and Labor opposition think the lights will stay on without coal-fired power.
How CSL became a gene therapy pioneer
CSL has created a world-first cure that is also the globe’s most costly drug — flipping the traditional model of big pharma on its head.
How GenesisCare flew too close to the sun
Its founder has quit, it has $2bn in debt and big investors are worried about its financial future. So what went wrong for the Australian medtech firm once slated to be the next CSL?
Banning gas would drive emissions explosion
With the Greens now demanding an immediate end to all gas projects, any semblance of a workable safeguard mechanism in this country has been hijacked by extremists.
Biotech firms told to ‘think bigger’
As Paul Perreault prepares to leave his role as chief executive of CSL, he shares his recipe for success after more than a decade at the helm of Australia’s biggest health company.
Smart tech fires up race for next blockbuster drug
At homegrown pharma giant CSL, medical innovation is about to really heat up.
CSL profit dips 8pc on takeover costs
All of the key divisions at Australia’s biggest health company have generated solid growth as plasma collections rebound from the pandemic.
ASX adds 0.2pc as Sims offset Star, Ansell falls
Shares end losing streak. Sims jumps on consensus beat. Challenger up on reaffirmed guidance. Star crashes to new low. Ansell and Temple & Webster dumped on profit slumps.
ASX jumps 0.6pc to fifth straight weekly gain
ASX 200 less than 1 per cent off its record. Commonwealth Bank closes at all-time high. CSL hits 15-month best. IAG falls on perils blowout. Iron ore miners fall on China prospects.
Meet the company planning to challenge CSL’s monopoly
Australian biotech Aegros has developed a TGA-approved plasma fractionation process that can double the yield of existing methods and make the country self-sufficient.
Original URL: https://www.theaustralian.com.au/topics/csl/page/4